Connect with us

Government

Switzerland Medical Cannabis Law Goes Live August 1

Published

on

Medical cannabis is just around the corner for citizens in Switzerland, with a program launching on August 1, and researchers are gearing up for numerous studies.

Starting on August 1, Switzerland’s medical cannabis law will officially launch. This news is the result of the amendment of the Swiss Narcotics Act, which the Federal Assembly (also referred to as the Swiss parliament) nearly a year-and-a-half ago. The medical cannabis ban was lifted by the Federal Council in June.

As of August 1, medical cannabis patients will be allowed to get prescriptions directly from their medical practitioners, rather than requiring permission from the Switzerland Federal Office of Public Health (FOPH). The amendment also allows for the exportation of medical cannabis, as long as authorized companies seek out approval from Swissmedic, which is responsible “authorization and supervision of therapeutic products.”

In a press release, the Federal Council stated that demand prompted the change due to increased demand. In this translation “BAG” is an abbreviation for Bundesamt für Gesundheit, or the Swiss Federal Office of Public Health.

“Up to now, cannabis for medicinal purposes has not been allowed to be cultivated, imported or processed into preparations without an exceptional permit. Treatment of patients with cannabis medicinal products that were exempt from authorization was only possible with an exceptional permit from the BAG and only in justified cases,” the Federal Council said in a translated press release. “The demand for such permits has increased in recent years. This is administratively complex delays treatment and no longer corresponds to the exceptional character provided for by the Narcotics Act. The Federal Council has therefore presented Parliament with an amendment to the law to remove the ban on cannabis for medical purposes, which was passed in March 2021. A narcotic prescription will still be required for such drugs.”

Currently, Switzerland will only allow CBD products with less than 1% THC, and recreational cannabis will remain illegal. However Switzerland is on track to launch its cannabis pilot program out of Basel, located in the northern part of the country in a partnership with the University of Basel, its psychiatric clinics, and the local government.

The program will allow approximately 400 people to purchase cannabis for recreational consumption sometime in September, according to an announcement from April 2022. Over the course of two-and-a-half years, participants will answer questions regarding mental and physical health. For the use of this study, cannabis will be provided by Pure Production.

Additionally, a study called “Züri Can – Cannabis with Responsibility” has been nearing  final approval, with the goal of examining the effectiveness of medical cannabis. The study was initially announced in September 2021, and on June 28 researchers confirmed that they had sent their application to the FOPH and the Cantonal Ethics Committee. There’s currently a waitlist for people interested in this study, with a total of 2,100 participants allowed.

Other recent studies confirm that the demand for cannabis is continually rising. A study conducted by the University of Geneva’s Department of Sociology and a consulting company called EBP Switzerland, entitled “Economic effects of current and alternative regulation in Switzerland,” found that cannabis legalization could be valued at $1.03 billion and bring 4,400 jobs to the country. Adrian Gschwend, Head of Policies and Implementation at the FOPH, explained the essential timing of this data. “The study comes precisely at the right time as the commission for social and healthcare issues of the national assembly has recently started a legislative proposal regarding the legalisation of cannabis,” Gschwend said, according to MyScience.com. “The results show that both the current illicit market as well as a liberal commercial market inflicts costs on the public while individuals generate big profits. We thus need a well-regulated market that ensures both protection for children and adolescents as well as health protection measure[s].”

Source: https://hightimes.com/news/switzerland-medical-cannabis-law-goes-live-august-1/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News